# FDA Approves Generic Olanzapine and Fluoxetine Combination Teva Pharmaceuticals USA, Inc. received FDA approval for a generic version of the olanzapine and fluoxetine combination oral medication, potentially reducing treatment costs for patients with bipolar depression and expanding Teva's portfolio in the psychiatric pharmaceutical market. The approval is expected to increase price competition in the combination antipsychotic-antidepressant segment, benefiting both insurers and patients while allowing Teva to capture market share from branded alternatives.